Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.
Saved in:
| Title: | Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies. |
|---|---|
| Authors: | Zhu X; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Alvarez EA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Umetsu SE; Department of Pathology, University of California, San Francisco, San Francisco, California., Chapman JS; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Chen LM; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Ueda S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Henderson S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Nguyen P; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Calabrese S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Russell J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Aguilar J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Smith SA; AstraZeneca (United Kingdom) , Cambridge, United Kingdom., Shah N; AstraZeneca (United Kingdom) , Cambridge, United Kingdom., Feeney L; AstraZeneca (United Kingdom) , Cambridge, United Kingdom., Van Ziffle J; Genomic Medicine Laboratory, University of California, San Francisco, San Francisco, California.; Institute for Human Genetics, University of California, San Francisco, San Francisco, California., Turski ML; Molecular Oncology Initiative, University of California, San Francisco, San Francisco, California., Ko AH; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Munster PN; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Ashworth A; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Collisson EA; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Aggarwal RR; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 01; Vol. 32 (9), pp. 1632-1640. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
